Brief: Lyell Immunopharma Announces Positive Clinical Data From Phase 1/2 Trial Of Lyl314 For The Treatment Of Aggressive Large B-Cell Lymphoma
17/06/2025 11:35
June 17 (Reuters) - Lyell Immunopharma Inc LYEL.O: LYELL IMMUNOPHARMA ANNOUNCES POSITIVE NEW CLINICAL DATA DEMONSTRATING HIGH RATES OF DURABLE COMPLETE RESPONSES FROM THE PHASE 1/2 TRIAL OF LYL314 FOR THE TREATMENT OF AGGRESSIVE LARGE B-CELL LYMPHOMA LYELL IMMUNOPHARMA INC - LYL314 HAS MANAGEABLE SAFETY PROFILE FOR OUTPATIENT ADMINISTRATION LYELL IMMUNOPHARMA INC - LYL314 SHOWS 88% OVERALL RESPONSE RATE, 72% COMPLETE RESPONSE RATE IN 3L+ PATIENTS LYELL IMMUNOPHARMA INC - 71% OF COMPLETE RESPONSE PATIENTS REMAIN IN RESPONSE AT 6 MONTHS Source text: ID:nGNX8qdbtb Further company coverage: LYEL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma